Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Identifies Possible Biomarker for Response to Atherosclerosis Candidate

NEW YORK (GenomeWeb News) - Millenium Pharmaceuticals said Tuesday it has identified a genomic biomarker during Phase II trials of a cardiovascular disease drug.
 
The company said it has found that 11.3 percent of patients treated with its MLN1202 monoclonal antibody had a reduction of C-reactive protein (CRP), and that CRP reductions were more likely in patients with a SNP that was identified in 53 percent of the study population.
 
The company also said MLN1202 lowered CRP levels similarly in subjects on lipid-lowering agents, such as statins, compared to those not on these agents, and that MLN1202 was well-tolerated with no evidence of systemic suppressed immunity.
 
"The association of a genomic biomarker with the biologic activity of the investigational drug validates our approach of using biomarkers to tailor drug treatments,” Millenium CSO Nancy Simonian said in a statement.

The Scan

Pig Organ Transplants Considered

The Wall Street Journal reports that the US Food and Drug Administration may soon allow clinical trials that involve transplanting pig organs into humans.

'Poo-Bank' Proposal

Harvard Medical School researchers suggest people should bank stool samples when they are young to transplant when they later develop age-related diseases.

Spurred to Develop Again

New Scientist reports that researchers may have uncovered why about 60 percent of in vitro fertilization embryos stop developing.

Science Papers Examine Breast Milk Cell Populations, Cerebral Cortex Cellular Diversity, Micronesia Population History

In Science this week: unique cell populations found within breast milk, 100 transcriptionally distinct cell populations uncovered in the cerebral cortex, and more.